245 related articles for article (PubMed ID: 1847458)
1. Identification of two determinants that attenuate vaccine-related type 2 poliovirus.
Ren RB; Moss EG; Racaniello VR
J Virol; 1991 Mar; 65(3):1377-82. PubMed ID: 1847458
[TBL] [Abstract][Full Text] [Related]
2. Mapping of attenuating sequences of an avirulent poliovirus type 2 strain.
Moss EG; O'Neill RE; Racaniello VR
J Virol; 1989 May; 63(5):1884-90. PubMed ID: 2539491
[TBL] [Abstract][Full Text] [Related]
3. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates.
Macadam AJ; Pollard SR; Ferguson G; Skuce R; Wood D; Almond JW; Minor PD
Virology; 1993 Jan; 192(1):18-26. PubMed ID: 8390752
[TBL] [Abstract][Full Text] [Related]
4. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine.
Bouchard MJ; Lam DH; Racaniello VR
J Virol; 1995 Aug; 69(8):4972-8. PubMed ID: 7609067
[TBL] [Abstract][Full Text] [Related]
5. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
[TBL] [Abstract][Full Text] [Related]
6. Mouse neurovirulence determinants of poliovirus type 1 strain LS-a map to the coding regions of capsid protein VP1 and proteinase 2Apro.
Lu HH; Yang CF; Murdin AD; Klein MH; Harber JJ; Kew OM; Wimmer E
J Virol; 1994 Nov; 68(11):7507-15. PubMed ID: 7933134
[TBL] [Abstract][Full Text] [Related]
7. Host range determinants located on the interior of the poliovirus capsid.
Moss EG; Racaniello VR
EMBO J; 1991 May; 10(5):1067-74. PubMed ID: 1850692
[TBL] [Abstract][Full Text] [Related]
8. Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing.
La Monica N; Meriam C; Racaniello VR
J Virol; 1986 Feb; 57(2):515-25. PubMed ID: 3003384
[TBL] [Abstract][Full Text] [Related]
9. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain.
Kohara M; Abe S; Komatsu T; Tago K; Arita M; Nomoto A
J Virol; 1988 Aug; 62(8):2828-35. PubMed ID: 2839704
[TBL] [Abstract][Full Text] [Related]
10. Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model.
Martin A; Benichou D; Couderc T; Hogle JM; Wychowski C; Van der Werf S; Girard M
Virology; 1991 Feb; 180(2):648-58. PubMed ID: 1846492
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell.
Couderc T; Hogle J; Le Blay H; Horaud F; Blondel B
J Virol; 1993 Jul; 67(7):3808-17. PubMed ID: 8389907
[TBL] [Abstract][Full Text] [Related]
12. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.
Tardy-Panit M; Blondel B; Martin A; Tekaia F; Horaud F; Delpeyroux F
J Virol; 1993 Aug; 67(8):4630-8. PubMed ID: 8392604
[TBL] [Abstract][Full Text] [Related]
13. Type 2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil.
Friedrich F; Da-Silva EF; Schatzmayr HG
Acta Virol; 1996 Feb; 40(1):27-33. PubMed ID: 8886095
[TBL] [Abstract][Full Text] [Related]
14. Nucleic acid sequence of the region of the genome encoding capsid protein VP1 of neurovirulent and attenuated type 3 polioviruses.
Stanway G; Cann AJ; Hauptmann R; Mountford RC; Clarke LD; Reeve P; Minor PD; Schild GC; Almond JW
Eur J Biochem; 1983 Oct; 135(3):529-33. PubMed ID: 6311539
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a rare natural intertypic type 2/type 3 penta-recombinant vaccine-derived poliovirus isolated from a child with acute flaccid paralysis.
Zhang Y; Wang H; Zhu S; Li Y; Song L; Liu Y; Liu G; Nishimura Y; Chen L; Yan D; Wang D; An H; Shimizu H; Xu A; Xu W
J Gen Virol; 2010 Feb; 91(Pt 2):421-9. PubMed ID: 19846676
[TBL] [Abstract][Full Text] [Related]
16. Localization of genomic regions specific for the attenuated, mouse-adapted poliovirus type 2 strain W-2.
Pevear DC; Oh CK; Cunningham LL; Calenoff M; Jubelt B
J Gen Virol; 1990 Jan; 71 ( Pt 1)():43-52. PubMed ID: 2154539
[TBL] [Abstract][Full Text] [Related]
17. Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients.
Li J; Zhang LB; Yoneyama T; Yoshida H; Shimizu H; Yoshii K; Hara M; Nomura T; Yoshikura H; Miyamura T; Hagiwara A
Arch Virol; 1996; 141(6):1047-54. PubMed ID: 8712922
[TBL] [Abstract][Full Text] [Related]
18. Genetic analysis of the attenuation phenotype of poliovirus type 1.
Omata T; Kohara M; Kuge S; Komatsu T; Abe S; Semler BL; Kameda A; Itoh H; Arita M; Wimmer E
J Virol; 1986 May; 58(2):348-58. PubMed ID: 3009852
[TBL] [Abstract][Full Text] [Related]
19. Attenuated poliovirus strain as a live vector: expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses.
Mattion NM; Reilly PA; DiMichele SJ; Crowley JC; Weeks-Levy C
J Virol; 1994 Jun; 68(6):3925-33. PubMed ID: 8189529
[TBL] [Abstract][Full Text] [Related]
20. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
Kohara M; Abe S; Yoshioka I; Nomoto A
Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
